Almirall SA (LBTSF)
15.35
0.00 (0.00%)
USD |
OTCM |
Aug 27, 16:00
Almirall Debt to Equity Ratio : 0.21 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.21 |
| December 31, 2025 | |
| June 30, 2025 | |
| December 31, 2024 | |
| June 30, 2024 | |
| December 31, 2023 | |
| June 30, 2023 | |
| December 31, 2022 | |
| June 30, 2022 | |
| December 31, 2021 | |
| June 30, 2021 | |
| December 31, 2020 | |
| June 30, 2020 |
| Date | Value |
|---|---|
| December 31, 2019 | |
| June 30, 2019 | |
| December 31, 2018 | |
| June 30, 2018 | |
| December 31, 2017 | |
| June 30, 2017 | |
| December 31, 2016 | |
| June 30, 2016 | |
| December 31, 2015 | 0.216 |
| June 30, 2015 | 0.2279 |
| December 31, 2014 | 0.236 |
| June 30, 2014 | 0.3477 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Laboratorios Farmaceúticos Rovi SA | 0.1537 |
| Eli Lilly & Co. | 1.621 |
| AstraZeneca PLC | 0.7166 |
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.706B |
| Total Liabilities (Quarterly) | 909.59M |
| Shareholders Equity (Quarterly) | 1.750B |
| Current Ratio | 2.308 |
| Net Debt Paydown Yield | -3.66% |